Bacainn Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial
Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial, Bacainn’s First Clinical Candidate for the Treatment of Ulcerative Colitis BT051 IND Clearance Phase 1 Clinical Trial Initiation CONCORD, Mass. — Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, announced today FDA’s [...]